Given thatTET2 clonal hematopoiesis of indeterminate potential (CHIP) mutations affect older adults (~5%)13, the importance of developing TET2-targeted therapies will only become more relevant as the population ages and the incidence of bothde novo and therapy-related MDS continues to rise. The gene discussed is TET2; the disease is myelodysplastic syndrome.